Â鶹Æƽâ°æ strengthens its leadership team with a NASH expert and announces that its Phase 1b trial in chronic HBV infected patients is on track with its FXR agonist EYP001
Lyon, February 27, 2018 – Â鶹Æƽâ°æ, a privately held biopharmaceutical company developing innovative new drug candidates by mimicking virus strategies to modulate host cellular functions, has today announced that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. Â鶹Æƽâ°æ also confirms that its Phase Ib trial evaluating the safety of EYP001 in chronic HBV infected patients is progressing well in Europe and in the Asia-Pacific region and is set to deliver its results in Q2 2018.
Read next in 'Press releases'
- Â鶹Æƽâ°æ announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Â鶹Æƽâ°æ annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
- Â鶹Æƽâ°æ annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1
- Â鶹Æƽâ°æ announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- Â鶹Æƽâ°æ announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
